iShares Gold Trust vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? iShares Gold Trust trades at $78.82 (market cap $61.51B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.64 (market cap $2.27B). The key difference: iShares Gold Trust is far larger — about 27.1× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.
| IAU | SLS | |
|---|---|---|
Market Cap | $61.51B | $2.27B |
Volume | 3,206,729 | 4,179,659 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $15.46 |
52-Week Low | $74.21 | $1.39 |
Typical Hold Time | 49 Days | — |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $78.87, up 2.35% today, but faces strong technical bearish signals with 13 of 13 moving averages indicating sell signals. The stock shows neutral momentum oscillators with RSI levels at 40.80 (6-day) and 31.31 (12-day) suggesting potential oversold conditions. Recent market sentiment reflects gold's sensitivity to interest rate expectations and Treasury yield movements.
Investment outlook remains cautious with technical indicators predominantly bearish and gold prices facing headwinds from rising yields. The stock's proximity to key support at $76-77 creates a critical level to watch, while Federal Reserve policy decisions on interest rates will likely drive near-term direction.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →